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Phytocannabinoids, bioactive products of the Cannabis Sativa plant, are increasingly being 
considered as potential treatments for Motor Neuron Disease (MND). One common in vitro model 
to study the mechanisms of MND, such as oxidative stress, is the motor-neuron like NSC-34 cell 
line differentiated with all-trans retinoic acid (atRA). 
 
The aims of the present study were threefold: (1) To characterise the response of differentiated 
NSC-34 to; the three phytocannabinoids D9-tetrahydrocannabinol (THC), cannabidiol (CBD), 
cannabichromene (CBC); Bediolâ whole medicinal cannabis extract; and the synthetic CB1 agonist 
arachidonyl-2′-chloroethylamide (ACEA) and antagonist AM 251. (2) To investigate the potential 
neuroprotective properties of THC, CBD, CBC and Bediolâ against H2O2-induced toxicity, and (3) 
to investigate the morphological outcomes of CB1 modulation during NSC-34 differentiation. 
 
Differentiated NSC-34s displayed increased viability when treated with subtoxic concentrations of 
THC and Bediolâ (p<0.05). Differentiation also resulted in increased viability of cells exposed to 
high concentrations of CBC (20µM, p<0.01) and ACEA (100µM, p<0.0005). Only Bediolâ showed 
potential antioxidant effects, reducing toxicity induced by 250 and 350µM H2O2 (p<0.05). Both 
atRA and ACEA promoted NSC-34 differentiation (p<0.0005, p<0.05 respectively) as well as 
neurite length and number. This effect, for ACEA only, was negated by the addition of AM 251 
(p<0.01). 
 
Taken together, these results support the key role of atRA-induced differentiation of NSC-34 cells 
when studying cannabinoid neuroprotection and suggest the therapeutic antioxidant potential of 
whole medicinal cannabis extract. They also support the potential role of CB1 activation in NSC-34 
differentiation, a result previously undocumented in this cell line. 
249 words   
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Introduction 
The Epidemiology and Cellular Mechanisms of Motor Neuron Disease 
Motor Neuron Disease (MND) is a fatal neurodegenerative disease characterised by the progressive 
functional decline of both upper and lower motor neurons.1 Onset of symptoms generally occurs 
between the ages of 50 - 65 with a mean survival time of 3-5 years.1-3 In Australia, MND carries an 
estimated prevalence of 8.7 per 100,000, significantly higher than 2.7 per 100,000 estimated 
throughout Europe and North America, although this may be due to global under reporting.2, 4 The 
economic cost of MND in Australia is estimated to exceed $430 million annually, particularly due 
to associated morbidity and early mortality.4  
 
MND cases can be classified into two distinct categories. The familial form of the disease (fMND) 
accounts for only 5-10% of MND cases diagnosed, with the remaining 90-95% of cases classified 
as sporadic (sMND). Mutations in over 30 genes have been associated with fMND, including those 
encoding the key antioxidant superoxide dismutase-1 (SOD1), TAR-DNA binding protein-43 
(TDP-43), and C9orf72.5, 6. The aetiology of sMND, on the other hand, remains elusive. Several 
environmental exposures have been implicated as sMND risk factors including agricultural 
pesticides, herbicides and certain industrial chemicals.7 Regular cyanobacterial blooms have also 
been linked to temporo-spatial clusters of sMND around rural waterways, such as Lake Wyangan 
near Griffith, NSW.8 
 
Both forms of the disease are characterised by similar mechanisms on the cellular level. These 
include oxidative stress, neuroinflammation, mitochondrial dysfunction, dysregulation of 
autophagosomal flux, glutamate excitotoxicity, disruption of cytoskeletal structure and protein 
aggregation.2 Many of these mechanisms are self-perpetuating though and much like the aetiology 
of sporadic cases, the true pathogenesis of MND remains a mystery. 
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To date, therapeutic approaches to MND have only achieved moderate success in symptom 
management, as opposed to the modification of disease progression 9. The only currently approved 
treatment for MND is riluzole, which acts to reduce excitotoxicity through the inhibition of 
presynaptic glutamate release.10  While riluzole has been demonstrated to increase mean survival 
time by 2-3 months under specific treatment criteria, its clinical use remains somewhat limited.11 As 
such, there remains an urgent need to elucidate the pathogenesis of MND in order to develop 
effective therapeutics effective in slowing disease progression. 
 
The Endocannabinoid System and Three Key Phytocannabinoids 
Over recent years, the endocannabinoid system has emerged as a target of particular therapeutic 
potential in the treatment of many chronic diseases.12 This system consists of the G-protein coupled 
endocannabinoid receptors, their endogenous ligands, and associated pathways for synthesis, 
transport and degradation.13 Two main endocannabinoid receptors, CB1 and CB2, have been 
successfully cloned and studied to date, although evidence strongly suggests the existence of 
more.14 CB1 receptors are generally expressed presynaptically on neuronal cells, and are one of the 
most highly expressed excitatory receptors in the nervous system.15, 16 CB2 receptors, on the other 
hand, are generally expressed by glial and immune cells.17 CB1 receptors act to increase mitogen 
activated protein kinase (MAPK) signalling and inhibit adenylyl cyclase,. They play a key role in 
neurodevelopment, pain modulation, short and long term plasticity, and cellular response to insult 
and injury.16,18 In neurodegeneration, endocannabinoid signalling is involved in cellular responses 
against neuroinflammation, oxidative stress and excitotoxicity.19   
 
Several key endogenous CB1 agonists have been identified to date, the main two being N-
arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). Anandamide acts a 
partial agonist at CB1 and CB2 receptors, while 2AG instead acts as full agonist at both.20, 21 
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Uniquely, both compounds are continuously synthesised by presynaptic neurons and as such CB1 
receptors exhibit relatively high endogenous occupancy rates, although the relative expression of 
endocannabinoids varies strongly by location.18 
 
Phytocannabinoids, bioactive products of the Cannabis Sativa L. plant, have long been used by 
humans for therapeutic benefit, with anecdotal evidence stretching back over 5000 years.20,22 To 
date, over 120 unique compounds have been identified from the Cannabis Sativa L, including the 
many derivatives of cannabigerol, terpenes, flavonoids and other polyphenols, many of which 
interact with the endocannabinoid system with varying efficacies.23, 24 Phytocannabinoids have also 
exhibited potential interactions with other key receptors and signalling pathways in the nervous 
system. These including the G-protein coupled receptors GPR55 and GPR18, transient receptor-
potential channels (TRPVs), 5-HT serotonin receptors, opioid receptors and peroxisome 
proliferator-activated receptors (PPARs).25, 26 A growing body of literature supports the therapeutic 
potential of phytocannabinoid treatment options for a wide range of conditions including 
neurodegeneration, chronic pain, inflammation, muscle spasticity and epilepsy.13, 20, 27-29  
 
First isolated in 1964, D9-tetrahydrocannabinol (THC) is one of the most widely studied 
phytocannabinoids to date.30 The psychoactive effects of THC are largely modulated by CB1 
receptors, to which it is a partial agonist with similar affinity to anandamide. Interestingly, 
relatively high levels of endogenous CB1 occupancy heavily affects the pharmacological effects of 
THC18 While the addition of THC at synapses where anandamide predominates may have an 
excitatory effect, it may have an antagonist effect in synapses predominated by 2AG.18 As such, 
THC modulation of CB1 receptors is much more nuanced than a simple agonist relationship, and 
activity heavily depends on the synaptic microenvironment. Indeed, treatment with high doses of 
the CB1 antagonist rimonabant only mildly ameliorated the psychoactive changes brought on 
THC.31  
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Cannabidiol (CBD) is another widely studied phytocannabinoid, exhibiting antioxidant, anti-
inflammatory properties and a wide safety profile for therapeutic use.32, 33 While void of 
psychoactive properties, recent evidence suggests that it may act as a weak allosteric antagonist of 
both CB1 and CB2 receptors.34 Another phytocannabinoid of therapeutic interest is the CB2 receptor 
agonist cannabichromene (CBC).35 While relatedly understudied compared to CBD and THC, it has 
been demonstrated to increase viability of adult neural progenitor stem cells via increased 
phosphorylation of extra-cellular signal related kinase (ERK).36 CBC has also been demonstrated to 
inhibit cellular uptake of anandamide, and play an anti-inflammatory role, potentially due to its role 
as a TRPV agonist. 37, 38 
 
THC, CBD and CBC all display promising therapeutic potential against certain mechanisms 
associated with motor neuron disease. Sativex, an oral spray containing THC and CBD, is currently 
approved for the treatment of muscle spasticity in multiple sclerosis, a neurodegenerative disease 
sharing many of the same toxicity mechanisms as MND.39  In a transgenic mouse model of MND, 
treatment with D9-tetrahydrocannabinol was found to increase both motor function and mean 
survival time. 40 Indeed, a phase III clinical trial investigating cannabidiol (CBD) oil as a novel 
therapeutic for MND is currently recruiting patients in Queensland, Australia.41  
 
One of the major critiques of both in vitro and in vivo MND research to date is the heavy reliance 
on fMND, particularly the murine SOD 1G93A  mutation.40 Despite accounting for the vast majority 
of cases, sMND by comparison is relatively understudied. As such, there is a need for a robust, non-
transgenic in vitro model to study cellular mechanisms of MND in more depth. 40, 42 
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The NSC-34 cell line 
The NSC-34 cell line is a hybrid between murine neuroblastoma and motor neuron-enriched 
embryonic spinal cord cells.43 While undifferentiated in their proliferative state, the combination of 
serum-starvation and all-trans retinoic acid (atRA) and has been demonstrated to induce a motor 
neuron-like state. These cells exhibit morphological changes such neuritic outgrowths and develop 
the ability to generate action potentials.11 Differentiated NSC-34s also express choline acetyl 
transferase (ChAT), neuronal growth markers such as the axonal protein b-Tubulin III, and are 
generally more resistant to neurotoxic events such as oxidative stress and glutamate 
excitotoxicity.42, 44 In addition, differentiation has been demonstrated cause a 5-fold increase NSC-
34 expression of CB1 receptors, suggesting that endocannabinoid signalling plays a key role in the 
survival of these cells post differentiation.19 This being said, there are several inconsistencies in the 
literature that still need to be addressed. 45 
 
Despite NSC-34 cells being regularly employed in the study of cholinergic neurodegeneration, a 
standardised differentiation protocol in yet to be developed and fully characterised. Reported 
differentiation times range from 48 hours to over 4 weeks, with atRA concentrations varying 
between 1µM and 10µM.19, 45, 46 By comparison, a small body of evidence suggests that 
differentiation may be independent of atRA treatment.45 In addition, several studies bypassed 
differentiation altogether.45 This highlights the need for a robust, standardised and well 
characterised protocol for NSC-34 differentiaton.45 
 
It has also been suggested that differentiated cells do not express all NMDA receptor subunits at 
sufficient quantities to provide an appropriate model for glutamate excitotoxicity. 45 While this cell 
line may not exhibit sustained calcium influx in response to treatment with glutamate, this does not 
necessarily invalidate their use in the study of neurodegenerative mechanisms. Indeed, treatment 
 9 
with the anti-excitotoxic treatment riluzole was unable to reduce cell death induced by the reactive 
oxygen species H2O2 or the protein kinase C inhibitor staurosporine, suggesting these toxicity 
pathways may be independent of glutamate signalling.44 As such, differentiated NSC-34s may still 
provide a suitable model for the study of other toxicity mechanisms associated with MND, such as 
oxidative stress. 
 
Interestingly, the addition of the potent and specific CB1 agonist arachidonyl-2′-chloroethylamide 
(ACEA) to serum-reduced differentiation media promoted differentiation of primary murine neural 
stem cells into motor neuronal cells, but not astrocytes or oligodenrocytes.47 This treatment caused 
a 2.5-fold increase in the percentage of cells expressing the axonal protein B-tubulin III, an effect 
that was negated in the presence of the specific CB1 antagonist AM 251. ACEA also increased the 
number of neurites per cell and the length of these neurites, two other morphometric indicators of 
neuronal differentiation.47 In light of this, CB1 activation may also play an important role in 
promoting morphological changes in differentiating NSC-34 cells.  
 
Aims and Hypotheses 
Based on the preceding literature, the author hypothesises that differentiation will alter NSC-34 
response to cannabinoid treatment, and hence any neuroprotective effects conferred against H2O2-
induced oxidative stress. Furthermore, CB1 receptor excitation during differentiation will promote 
the formation of motor-neuron like morphological changes seen in NSC-34s. To this end, the 
present study aims to; (1) characterise the effect of differentiation with all-trans retinoic acid on 
NSC-34 response to the phytocannabinoids D9-tetrahydrocannabinol, cannabidiol, cannabichromene 
and the whole medicinal cannabis extract Bediolâ; (2) investigate the effect of differentiation on 
NSC-34 response to H2O2-induced oxidate stress and any neuroprotective properties conferred by 
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these cannabinoids; and (3) investigate the effects of CB1 receptor modulation during NSC-34 
differentiation on the morphological outcomes of the process. 
 
MATERIALS AND METHODS 
Chemicals and Reagents 
Dulbecco's Modified Essential Medium (DMEM, D6429), Penicillin/Streptomycin (P/S), Non-
essential amino acids (NEAA), all-trans retinoic acid (atRA), 30% hydrogen peroxide (H2O2), 
arachidonyl-2′-chloroethylamide (ACEA), phosphate buffered saline (PBS, pH=7.4), 10x Trypsin 
EDTA, and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St 
Louis, MO, USA). Dimethyl Sulfoxide (DMSO) and Ethanol were obtained from Chem-Supply 
(Port Adelaide, SA, Australia) and Trypan Blue from Bio-Rad Laboratories (Gladesville, NSW, 
Australia). 
 
D9-Tetrahydrocannabinol was obtained from the National Measurement Institute (Department of 
Industry, Science, Energy and Resources, ACT, Australia), cannabidiol from Cerlliant Analytical 
Reference Standards (Round Rock, TX, USA) and cannabichromene from Sapphire Bioscience 
(Redfern, NSW, Australia). Bediolâ whole medicinal cannabis extract, containing 8% CBD and 
6.3% THC, was sourced from Novachem (Heidelberg West, VIC, Australia). Bediolâ was extracted 
at 100mg/ml in 100% ethanol and all dilutions calculated by primary constituent (CBD). All 
chemicals and reagents used were of an analytical grade. 
 
NSC-34 Cell Culture and Differentiation 
NSC-34 were kindly donated by Dr Hakan Muyderman (Flinders University, SA, Australia), and 
maintained in DMEM supplemented with 5% FBS, 1% penicillin/streptomycin and 1% NEAA.42, 48 
Cells were split every three days and maintained at 37oC under 5% CO2. 
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For cannabinoid-response and oxidative-stress induced toxicity experiments NSC-34 cells were 
trypsinised and seeded into 96-well plates at a density of 1 x 104 cells per well (3x104 cells per cm2) 
in 100µl DMEM supplemented with 5% FBS. After 24 hours seeding, media was replaced with 
differentiation media consisting of DMEM supplemented with 10µM all-trans retinoic acid, 1% 
FBS, 1% P/S and 1% NEAA. After 48 hours differentiation, approximately half of the cells 
exhibited motor-neuron like morphology, with long neuritic projections visible under light 




Figure 1: Light microscopy of (a) undifferentiated NSC-34 cells, and (b) NSC-34 cells after 48 
hour differentiation in the presence of 10µM all-trans Retinoic Acid and 1% FBS (x200 
magnification) 
 
Cannabinoid Concentration-Response and Toxicity 
After differentiation, media was removed and replaced with serum-free DMEM containing 10nM-
100µM of CBD, THC and ACEA for 24 hours. Due to solubility constraints, CBC and AM 251 
were instead treated at 10nM-20µM. For a more therapeutically aligned comparison, Bediolâ whole 
cannabis extract containing 8% CBD and 6.3% THC was also tested. Undifferentiated NSC-34s 
(a) (b) 
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were treated under the same conditions. Vehicle controls were included for 1% DMSO, 0.1% 
DMSO, 1.36% ethanol and 3.14% methanol. All treatment conditions were performed in triplicate, 
and experiments repeated three times over consecutive passages. 
 
H2O2-Induced Oxidative Stress and Cannabinoid Neuroprotection 
Differentiated NSC-34 cells were treated with serum-free DMEM containing 1µM THC, CBD, 
CBC or Bediolâ standardised to 1µM CBD equivalent. After 1 hour of cannabinoid pre-treatment, 
serial dilutions of 50, 150, 250, 350 and 450µM H2O2 were added, and cells incubated for a further 
24 hours. All treatment conditions were performed in triplicate, and experiments repeated four 
times over consecutive passages. 
 
MTT Cytotoxicity Assay 
Following treatment, cell viability was assessed using the thiazolyl blue tetrazolium bromide (MTT) 
colorimetric cytotoxicity assay.49 Briefly, treatment media was replaced with serum-free DMEM 
containing 0.25mg/ml MTT. After two hours, active mitochondria had converted MTT to an 
insoluble blue formazan salt, which was dissolved by replacing media with 100µl DMSO per well. 
Plates were agitated for 30 seconds to ensure homogeneity and absorbance at 570nm determined 
using a Synergy MX microplate reader (Biotek Instruments Inc., Winooski, VT, USA).  
  
Morphometric Analysis of NSC-34 Differentiation 
For morphometric analysis, Ibidi 8-slide live cell imaging slide wells were seeded with 3 x 104 cells 
per cm2 in 300µl proliferation medium. Cells were then differentiated for 48 hours in 1% DMEM 
supplemented with 10µM atRA, 1µM ACEA or a combination of the two. These conditions were 
then repeated with the addition of the synthetic CB1 antagonist AM 251 (1µM). After 
differentiation, cells were imaged using a Ti-E Live Cell Imaging System (Nikon Corporation, 
Tokyo, Japan). Four images were analysed per well using a variation of the Scholl method for 
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quantification of dendritic branching, a method previously used to asses differentiation outcomes 
both in NSC-34s and other neuronal cell lines.45, 50, 51. Briefly, 20 cells were randomly selected for 
tracing from a 0.16cm2 area using the Mersenne-Twister random number generator. Neurites were 
traced from the centre of the soma using the NeuronJ plugin for ImageJ (Version 1.53) and cells 
considered differentiated if they possessed at least one neurite longer that 50µM.45, 52 From this 
tracing data the percentage of cells differentiated, average neuritic length per differentiated cell and 
the number of neurites per differentiated cell were calculated. Experiments were repeated four 
times, resulting in the tracing of over 300 cells per treatment condition. 
  
Statistical Analysis 
All data was processed and analysed using Prism 9.0.0 for Mac (GraphPad Software, CA, USA). 
MTT absorbance data was averaged between technical replicates and standardised. Results were 
expressed as a percentage of cannabinoid-free control for concentration-response experiments, or 
H2O2-free control for oxidative stress toxicity experiments. Two-way ANOVA tests with 
Bonferroni Post-Hoc tests were performed on all results. p>0.05 was considered statistically 




To determine the appropriate cannabinoid treatment concentrations for further study, concentration 
response data was determined for; the three phytocannabinoids, CBD, THC and CBC; Bediolâ 
whole medicinal cannabis extract; and the synthetic CB1 ligands ACEA and AM 251 (Figure 2).  
  
CBD elicited a similar response under both conditions, with a significant decrease in cell viability 
detected at 10µM (p<0.0005). CBC resulted in toxicity at 20µM (p<0.01) in undifferentiated cells, 
but increased cell viability in the differentiated cells (+18.9 ± 9.0%, p<0.01). Treatment with 1µM 
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THC also increased cell viability by 23.1 ± 4.8% (p<0.01) in differentiated cells only although this 
was followed by a sharp decrease in viability of both cell types at 10µM (differentiated p<0.05, 
undifferentiated p<0.0005). Bediolâ elicited a similar response curve to THC, with toxicity seen at 
10µM CBD equivalent under both differentiation conditions (p<0.0005) but increased viability at 
1µM CBD equivalent in differentiated cells only (+31.6 ± 7.0%, p<0.005). 
  
The synthetic CB1 agonist ACEA caused a minor reduction in cell viability at 100µM in the 
undifferentiated NSCs (p<0.01), although this effect was reversed with a 55.5 ± 4.4% (p<0.0005) 
increase in differentiated cells. 10µM AM 251, on the other hand caused significant toxicity to 
NSC-34s that were both differentiated (p<0.0005) and undifferentiated (p<0.01). 
  
Based on the results above, 1µM was chosen as the most appropriate concentration of cannabinoid 
treatment for further studies. 
 
Significant vehicle toxicity (not displayed) was not detected for the highest concentrations of 
methanol (3.14%) and ethanol (1.36%) in both differentiated and undifferentiated cells. 1% DMSO 
was well tolerated by undifferentiated cells but resulted in a 26.5 ± 2.4% increase in differentiated 
cell viability (p<0.05). This effect was not seen from the 0.1% DMSO vehicle present at 10µM 




Figure 2: 48 hour differentiation with 10µM all-trans retinoic acid altered NSC-34 response to (a) 
cannabidiol (CBD), (b) D9-tetrahydrocannabinol (THC) (c) cannabichromene (CBC); (d) Bediolâ 
whole medicinal cannabis extract; (e) arachidonyl-2′-chloroethylamide (ACEA), and (f) AM 251. 
Data is displayed as mean ± SEM, where n=3. *p<0.05, **p<0.01, ***p<0.005, ****p<0.0005 vs. 
cannabinoid-free control. 







































































































































H2O2-Induced Oxidative Stress 
To investigate potential antioxidant effects of cannabinoids under investigation, differentiated and 
undifferentiated NSCs were co-treated for 24 hours with H2O2 and 1µM CBD, THC, CBC or 
Bediolâ standardised to 1µM CBD equivalent (Figure 3). 
  
Both undifferentiated and differentiated NSCs displayed a concentration-dependent toxicity 
response to H2O2-induced oxidative-stress, with a large reduction in viability at 450µM H2O2 (32.6 
± 6.6% vs. 31.3 ± 1.3% respectively) 
  
None of the cannabinoids under review displayed any significant neuroprotective effects on 
undifferentiated NSC-34 cells over any concentrations of H2O2, as determined via MTT assay. This 
result was mirrored in the differentiated cells co-treated with 1µM CBD or CBC. 1µM THC 
treatment on the other hand increased differentiated cell viability in the presence of 0 and 50µM 
H2O2 (p<0.05), although this effect was absent at higher H202 concentrations. Bediolâ, on the other 
hand displayed no significant effects at low concentrations of H2O2 but reduced toxicity induced by 






 Figure 3: Comparison of the effects of 1-hour pre-treatment of (a) D9-tetrahydrocannabinol (THC, 
1µM) and cannabidiol (CBD 1µM), or (b) cannabichromene (CBC 1µM) and Bediolâ whole 
medicinal cannabis extract (CBD equivalent, 1µM) on H2O2 induced neurotoxicity in differentiated 
NSC-34 cells. Data is displayed from undifferentiated cells for comparison; (c) and (d) respectively. 
Data displayed as mean ± SEM, where n=4. *p<0.05 vs. untreated control. 
  




















































































Morphometric Analysis of NSC-34 Differentiation 
Minimal differentiation was observed when NSC-34 were treated for 48 hours in DMEM 
containing only 1% FBS. Only 7.6 ± 3.3% of cells exhibiting at least one neurite longer than 50µm 
(Figure 4.a). This percentage increased when differentiation media was supplemented with 10µM 
atRA (38.1 ± 6.1%, p<0.0005), 1µM ACEA (27.1 ± 5.0%, p<0.05) or a combination of the two 
(51.3 ± 2.7%, p<0.0005). Indeed, the combination of atRA and ACEA increased the number of cells 
differentiated beyond that of ACEA alone (p<0.01) but not atRA. 
 
All three conditions also increased the average length of neurites in cells that did undergo 
differentiation (atRA: 160.3 ± 23.0 µm, ACEA: 135.7 ± 10.9 µm, combined: 167.3 ± 12.3 µm vs. 
control: 59.9 ± 6.0µm) (Figure 4.b) as well as the average number of neurites longer than 50µm per 
differentiated cell (atRA: 1.59 ± 0.18, ACEA: 1.50 ± 0.12, combined: 1.73 ± 0.09 vs. control: 1.00 
± 0.0) (Figure 4.c).  
 
To investigate the role that CB1 receptors play in NSC-34 differentiation, experiments were 
repeated in the presence of the competitive CB1 antagonist AM 251 (1µM). AM 251 significantly 
negated all three morphological changes under investigation (7.8 ± 2.9% differentiated, 69.7 ± 11.2 
µm average neurite length and 1.13 ± 0.09 neurites per differentiated cell) induced by coincubation 
with 1µM ACEA alone, but not that induced by atRA or the combination of the two (Figure 5). It 
should also be noted that 1µM AM 251 alone did not significantly alter any morphological 




Figure 4: Morphological changes were increased in NSC-34 cells after 48 hour differentiation in 
serum-reduced (1% FBS) DMEM supplemented with all-trans Retinoic Acid (atRA, 10µM), 
arachidonyl-2′-chloroethylamide (ACEA, 1µM) or the combination of the two when compared to 
differentiation media alone. (a) The percentage of cells displaying neuritic growths longer than 
50µm, (b) the average neuritic length of differentiated cells, and (c) average number of neurites per 
differentiated cell all significantly rose under all three conditions. Data is displayed as mean ± SEM 
















































































































Figure 5: Motor-neuron like morphological changes induced by 48 hour coincubation with 
arachidonyl-2′-chloroethylamide (ACEA, 1µM), but not all-trans Retinoic Acid (atRA, 10µM), 
were reduced by the addition of the synthetic CB1 antagonist AM 251 (1µM). These changes 
include (a) the percentage of cells displaying neuritic growths longer than 50µm, (b) the average 
neuritic length of differentiated cells, and (c) the average number of neurites per differentiated cell. 








































































































In order to characterise how differentiation affects NSC-34 cellular responses to cannabinoid 
treatments and determine appropriate treatment concentrations for further study, concentration-
response curves were developed for; the phytocannabinoids CBD, THC, CBC; and the whole 
medicinal cannabis extract Bediolâ. The potent, specific CB1 agonist ACEA and antagonist AM 
251 were also investigated for a more thorough understanding of the role of CB1 receptors. 
 
Interestingly, differentiated NSC-34 viability increased at 1µM THC and then dropping away at 
higher concentrations. This effect suggests that THC plays a neuroprotective role in these cells at 
lower concentrations prior to reaching toxicity. The CB1 agonist ACEA elicited a similar response, 
albeit cell viability increased only at a much higher concentration (100µM), implying that this 
neuroprotective effect seen may be mediated by the CB1 receptors expressed in higher quantities by 
these cells post-differentiation.47  Differentiated NSC-34s also displayed a hormetic increase in cell 
viability to Bediolâ whole medicinal cannabis extract standardised to 1µM by CBD concentration.  
 
In terms of oxidative stress, differentiation did not appear to alter NSC-34 response to H2O2 toxicity 
alone. Indeed, while THC did play a neuroprotective role at low and absent H2O2 concentrations, 
none of the phytocannabinoids studied displayed individual antioxidant properties against H2O2 in 
either differentiated or differentiated cells. 
 
Bediolâ on the other hand did display an antioxidant effect, reducing toxicity induced by 250 and 
350µM H2O2 in differentiated NSC-34 cells only. It should be noted that a 1µM CBD equivalent 
treatment of Bediolâ also included 787nM THC, along with unknown quantities of unspecified 
phytocannabinoids. Hence, the neuroprotective and anti-inflammatory properties seen may also be 
due to over 120 phytocannabinoids potentially present in the extract.23 Furthermore, it has 
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previously been suggested that the combination of multiple cannabinoids may bestow 
neuroprotective effects greater than the sum of the individual phytocannabinoids. 53 54 
 
Not only did atRA-induced differentiation modulate cellular responses to THC, CBC, ACEA and 
Bediolâ, it also potentiated the antioxidant effects of Bediolâ. These results suggest that 
differentiation of NSC-34s is an essential step when investigating cannabinoids as novel 
therapeutics.  
 
Differentiation of NSC-34s for 48 hours in media supplemented with 10µM atRA and 1% FBS 
significantly increased the percentage of cells presenting neuritic growths when compared to the 
serum-reduced media alone. This result was consistent across the two other morphological 
indicators of differentiation assessed, average length and number of these growths per differentiated 
cell. Together these three morphological changes provide further support the essential role of 
differentiation in determining NSC-34 cellular response to treatment conditions. These results also 
confirm the suitability of the differentiation protocol (10µM atRA, 1% FBS, 48h) used in prior 
studies.  
 
The CB1 agonist ACEA also induced motor-neuron like morphological changes in NSC-34s, a 
novel effect previously undocumented in this cell line. The addition of AM 251 negated these 
morphological changes due to ACEA, but not atRA, further supporting the notion that these 
changes were due to interaction with CB1 receptors. The combination of these two pro-
differentiation compounds did not increase morphological changes beyond that of the two 
individually, suggesting that these effects may not be cumulative. Further study is required on this 
front to fully elucidate the mechanisms behind CB1 induced differentiation of NSC-34s. 
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One of the main limitations of assessing differentiation solely on cellular morphology is the 
relatively low percentage of cells that take on these morphological changes. In previous studies, 
only 40% of cells were considered differentiated after a 4 day differentiation with 1µM atRA, and 
only 20% of primary neural stem cells differentiated with ACEA expressed similar morphology42, 
44. This being said, differentiation is a complex, multifactorial process and basic morphology does 
not fully reflect how a cell will act physiologically. To this end, the author proposes further study of 
ACEA-induced NCS-34 differentiation focusing on expression of key motor-neuronal features, 
such as choline acetyl transferase and glutamate receptors.  
 
The results presented in the present study open up many exciting avenues for further investigation. 
While atRA differentiation caused significant morphological changes to NSC-34s, and heavily 
modified cellular responses to cannabinoid treatments, further work is required to test the 
consistency and physiological extent of these changes. CB1 activation, such as via the synthetic 




MND is a complex, multifactorial, poorly understood disease and hence poses many challenges to 
the development of novel therapeutics. Based on the findings of the present study, treatment of 
NSC-34 cells with 10µM all-trans retinoic acid for 48 hours successfully promotes differentiation. 
Interestingly, the synthetic CB1 agonist ACEA promoted similar morphological changes, a novel 
effect previously undocumented in this cell line. Differentiation modulates NSC-34 cells response 
to cannabinoid treatment. It also potentiates the antioxidant effects of Bediolâ whole medicinal 
cannabis extract against H2O2-induced toxicity, adding to the growing body of literature supporting 
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